134 related articles for article (PubMed ID: 17141957)
1. Evidence for an extended interacting surface between beta-amyloid and serum amyloid P component.
Likó I; Mák M; Klement E; Hunyadi-Gulyás E; Pázmány T; Medzihradszky KF; Urbányi Z
Neurosci Lett; 2007 Jan; 412(1):51-5. PubMed ID: 17141957
[TBL] [Abstract][Full Text] [Related]
2. Glycosaminoglycans inhibit neurodegenerative effects of serum amyloid P component in vitro.
Urbányi Z; Forrai E; Sárvári M; Likó I; Illés J; Pázmány T
Neurochem Int; 2005 May; 46(6):471-7. PubMed ID: 15769549
[TBL] [Abstract][Full Text] [Related]
3. Use of genetically altered mice to study the role of serum amyloid P component in amyloid deposition.
Maeda S
Amyloid; 2003 Aug; 10 Suppl 1():17-20. PubMed ID: 14640037
[TBL] [Abstract][Full Text] [Related]
4. Binding epitopes and interaction structure of the neuroprotective protease inhibitor cystatin C with beta-amyloid revealed by proteolytic excision mass spectrometry and molecular docking simulation.
Juszczyk P; Paraschiv G; Szymanska A; Kolodziejczyk AS; Rodziewicz-Motowidlo S; Grzonka Z; Przybylski M
J Med Chem; 2009 Apr; 52(8):2420-8. PubMed ID: 19317448
[TBL] [Abstract][Full Text] [Related]
5. Preferential association of serum amyloid P component with fibrillar deposits in familial British and Danish dementias: similarities with Alzheimer's disease.
Rostagno A; Lashley T; Ng D; Meyerson J; Braendgaard H; Plant G; Bojsen-Møller M; Holton J; Frangione B; Revesz T; Ghiso J
J Neurol Sci; 2007 Jun; 257(1-2):88-96. PubMed ID: 17374542
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory effect of minocycline on amyloid beta fibril formation and human microglial activation.
Familian A; Boshuizen RS; Eikelenboom P; Veerhuis R
Glia; 2006 Feb; 53(3):233-40. PubMed ID: 16220550
[TBL] [Abstract][Full Text] [Related]
7. An intramolecular O-N migration reaction on gold surfaces: toward the preparation of well-defined amyloid surfaces.
Boussert S; Diez-Perez I; Kogan MJ; de Oliveira E; Giralt E
ACS Nano; 2009 Oct; 3(10):3091-7. PubMed ID: 19772298
[TBL] [Abstract][Full Text] [Related]
8. Restored degradation of the Alzheimer's amyloid-beta peptide by targeting amyloid formation.
Crouch PJ; Tew DJ; Du T; Nguyen DN; Caragounis A; Filiz G; Blake RE; Trounce IA; Soon CP; Laughton K; Perez KA; Li QX; Cherny RA; Masters CL; Barnham KJ; White AR
J Neurochem; 2009 Mar; 108(5):1198-207. PubMed ID: 19141082
[TBL] [Abstract][Full Text] [Related]
9. Complement component C1q inhibits beta-amyloid- and serum amyloid P-induced neurotoxicity via caspase- and calpain-independent mechanisms.
Pisalyaput K; Tenner AJ
J Neurochem; 2008 Feb; 104(3):696-707. PubMed ID: 17986223
[TBL] [Abstract][Full Text] [Related]
10. Serum amyloid p component as a biomarker in mild cognitive impairment and Alzheimer's disease.
Verwey NA; Schuitemaker A; van der Flier WM; Mulder SD; Mulder C; Hack CE; Scheltens P; Blankenstein MA; Veerhuis R
Dement Geriatr Cogn Disord; 2008; 26(6):522-7. PubMed ID: 19052452
[TBL] [Abstract][Full Text] [Related]
11. Preparative capillary electrophoresis and mass spectrometry for the identification of a putative heparin-binding site in amyloid P component.
Heegaard NH; Roepstorff P
J Capillary Electrophor; 1995; 2(5):219-23. PubMed ID: 9384779
[TBL] [Abstract][Full Text] [Related]
12. The N-domain of angiotensin-converting enzyme specifically hydrolyzes the Arg-5-His-6 bond of Alzheimer's Abeta-(1-16) peptide and its isoAsp-7 analogue with different efficiency as evidenced by quantitative matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.
Toropygin IY; Kugaevskaya EV; Mirgorodskaya OA; Elisseeva YE; Kozmin YP; Popov IA; Nikolaev EN; Makarov AA; Kozin SA
Rapid Commun Mass Spectrom; 2008; 22(2):231-9. PubMed ID: 18085519
[TBL] [Abstract][Full Text] [Related]
13. Crystal structure of a decameric complex of human serum amyloid P component with bound dAMP.
Hohenester E; Hutchinson WL; Pepys MB; Wood SP
J Mol Biol; 1997 Jun; 269(4):570-8. PubMed ID: 9217261
[TBL] [Abstract][Full Text] [Related]
14. Binding of zinc(II) and copper(II) to the full-length Alzheimer's amyloid-beta peptide.
Tõugu V; Karafin A; Palumaa P
J Neurochem; 2008 Mar; 104(5):1249-59. PubMed ID: 18289347
[TBL] [Abstract][Full Text] [Related]
15. Identification of novel APP/Abeta isoforms in human cerebrospinal fluid.
Portelius E; Brinkmalm G; Tran AJ; Zetterberg H; Westman-Brinkmalm A; Blennow K
Neurodegener Dis; 2009; 6(3):87-94. PubMed ID: 19229112
[TBL] [Abstract][Full Text] [Related]
16. Catabolic attacks of membrane-bound angiotensin-converting enzyme on the N-terminal part of species-specific amyloid-beta peptides.
Sun X; Becker M; Pankow K; Krause E; Ringling M; Beyermann M; Maul B; Walther T; Siems WE
Eur J Pharmacol; 2008 Jun; 588(1):18-25. PubMed ID: 18495113
[TBL] [Abstract][Full Text] [Related]
17. Minocycline does not affect amyloid beta phagocytosis by human microglial cells.
Familian A; Eikelenboom P; Veerhuis R
Neurosci Lett; 2007 Apr; 416(1):87-91. PubMed ID: 17317005
[TBL] [Abstract][Full Text] [Related]
18. Modification of amyloid-beta(1-40) by a protease inhibitor creates risk of error in mass spectrometric quantitation of amyloid-beta(1-42).
Conboy JJ; Wood KG; Lame ME; Durham RA; Geoghegan KF
Anal Biochem; 2008 Nov; 382(2):147-9. PubMed ID: 18706385
[TBL] [Abstract][Full Text] [Related]
19. P-glycoprotein efflux and other factors limit brain amyloid beta reduction by beta-site amyloid precursor protein-cleaving enzyme 1 inhibitors in mice.
Meredith JE; Thompson LA; Toyn JH; Marcin L; Barten DM; Marcinkeviciene J; Kopcho L; Kim Y; Lin A; Guss V; Burton C; Iben L; Polson C; Cantone J; Ford M; Drexler D; Fiedler T; Lentz KA; Grace JE; Kolb J; Corsa J; Pierdomenico M; Jones K; Olson RE; Macor JE; Albright CF
J Pharmacol Exp Ther; 2008 Aug; 326(2):502-13. PubMed ID: 18499745
[TBL] [Abstract][Full Text] [Related]
20. Binding of human serum amyloid P-component to phosphocholine.
Christner RB; Mortensen RF
Arch Biochem Biophys; 1994 Nov; 314(2):337-43. PubMed ID: 7979374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
